

# AFRICAN REGULATORY CONFERENCE

## A forum for regulatory authorities and the pharmaceutical industry

FEBRUARY 5-6, 2008 | INDABA HOTEL, FOURWAYS JOHANNESBURG, SOUTH AFRICA



### ABOUT THE DRUG INFORMATION ASSOCIATION (DIA)

With almost 20,000 members worldwide, the Drug Information Association (DIA) is the premier member-driven organization encompassing the full continuum of disciplines in the pharmaceutical and related industries. The mission of DIA is to serve and develop members by providing a neutral, global forum that promotes the exchange of information critical to their professional performance and achievement. The goal of DIA is to be the most effective means for members to obtain the knowledge they need to advance their career, their profession, and their organization.

### ABOUT THE EUROPEAN FEDERATION OF PHARMACEUTICAL INDUSTRIES & ASSOCIATIONS (EFPIA)

EFPIA is the voice of the pharmaceutical industry in Europe. Through its membership, EFPIA represents 2,100 companies committed to researching, developing, and bringing to patients new medicines that improve health and quality of life around the world. The mission of EFPIA is to improve the competitiveness of the research-based pharmaceutical industry in Europe in a regulatory and political environment, which above all stimulates R&D and rewards innovation.

### ABOUT THE SOUTHERN AFRICAN DEVELOPMENT COMMUNITY (SADC)

SADC consists of 14 Member States (approximately 200 million people): Angola, Botswana, the Democratic Republic of Congo, Lesotho, Madagascar, Malawi, Mauritius, Mozambique, Namibia, South Africa, Swaziland, United Republic of Tanzania, Zambia and Zimbabwe. SADC's clear mission statement is "To promote sustainable and equitable economic growth and socio-economic development through efficient productive systems, deeper co-operation and integration, good governance, and durable peace and security, so that the region emerges as a competitive and effective player in international relations and the world economy". This mission is anchored on the common values and principles and the historical and cultural affinities that exist between the peoples of Southern Africa."



### Conference Chairperson

**Prof. Trevor M. Jones, CBE**, Kings College London, UK; Recently WHO Commissioner CIPIH

### Programme Committee

**Ms. Engela Dedwith**, Eli Lilly, South Africa, Area Regulatory Advisor  
**Ms. Fabienne Hanser**, Hoffmann-La Roche Ltd, Switzerland, Regulatory Manager  
**Mr. Afschin Khodaverdi-Afaghi**, Bayer Schering Pharma AG, Germany, Regulatory Head  
**Ms. Lynne Scarlett**, AstraZeneca UK Limited, UK, Associate Regulatory Director  
**Mr. Jonothan Shaw**, (Co-chairperson), Pfizer Ltd, UK, Associate Regulatory Director  
**Mr. Sheel Talwar**, (Chairperson), GlaxoSmithKline, UK, Regulatory Director  
**Ms. Visda Vaghayenagar**, sanofi-aventis, France, Regulatory Head  
**Mr. Colin Vickers**, Pfizer Ltd, UK, Head, International Regulatory Affairs

### Programme Advisors

**Mr. Joseph Mthetwa**, SADC, Senior Programme Manager for Healthcare and Pharmaceuticals  
**Ms. Lebogang Lebese**, SADC, Technical Advisor for Health

### Background

This is the first DIA/SADC co-sponsored African Regulatory Conference in partnership with the Africa Regulatory Network (ARN). The ARN is an ad hoc regional network of EFPIA. The ARN works in partnership with regulatory authorities and the pharmaceutical industry in Africa to develop legislation and regulatory practices that enable patients to have access to good quality medicines, including innovative medicines.

### Themes and Objectives

This first conference offers the opportunity to:

- Promote partnerships between African regulatory authorities and the pharmaceutical industry
- Facilitate open discussion on current topics important to the region
- Raise awareness of the regulatory environment and promote exchange of information
- Share views on expectations, benefits and challenges to regulatory harmonisation

Presentations will be given by international speakers, including regulators. The format of the conference will include panel discussions to maximise contributions around the key topics.

### Key Topics

- R&D industry and its role in providing access to new medicines
- Updates on global and regional regulatory developments
  - Recent developments in EU regulations
  - International Conference on Harmonisation Global Cooperation Group (ICH GCG)
  - SADC Harmonisation
- Quality Risk Management and the Pharmaceutical Inspection Co-operation Scheme
- Certification – The CPP and its role in earlier patient access to medicines
- Anti-counterfeiting initiatives

### Target Audience

Regulatory Affairs Professionals, Regulatory Authorities and other professionals involved in or interested in the pharmaceutical regulatory aspects of Quality/GMP, Anti-counterfeiting, and Harmonisation initiatives in the African region.

The final programme agenda will be available on DIA's website [www.diahome.org](http://www.diahome.org) and EFPIA's website [www.efpia.eu](http://www.efpia.eu) in early November 2007. Please check these websites for additional information and registration.

## Monday, February 4, 2008

18:00– Registration  
20:00

## Tuesday, February 5, 2008

07:30 Registration and Welcome Coffee

### 08:30– OPENING SESSION

09:40 *Session Objectives:* Conference opening and statement of meeting objectives.

#### INTRODUCTORY REMARKS BY CONFERENCE CHAIRPERSON

Prof. Trevor M. Jones, CBE, Kings College London, UK

#### KEYNOTE ADDRESS

Speaker Invited

#### WELCOME BY CO-SPONSORS/ARN

Mr. Joseph Mthetwa, SADC, Senior Programme Manager for Healthcare and Pharmaceuticals

Dr. Yves Juillet, LEEM (Les Entreprises du Médicament)/IFPMA, France, Senior Advisor; DIA Board Member

Mr. Sheel Talwar, GlaxoSmithKline, UK, Regulatory Director; ARN Representative

### 09:40– SESSION 1

#### 10:10 PHARMACEUTICAL R&D INDUSTRY GOING FORWARD

*Session Objectives:* The contribution to world health by the pharmaceutical industry and the challenges going forward will be discussed.

#### The Importance of Pharmaceutical R&D

Prof. Trevor M. Jones, CBE, Kings College London, UK

10:10– Coffee Break  
10:40

### 10:40– SESSION 1 continued

12:00

#### 10:40 Role of Africa in Clinical Development – Regulatory Implications

Dr. Lynn Katsoulis, Cato Research, Associate Director, Drug Development

#### 11:10 Accelerating Access of Medicines to Address Diseases of Public Health Importance

WHO Speaker Invited

#### 11:40 Panel Discussion

12:00– Lunch Break  
13:30

### 13:30– SESSION 2

#### 15:00 GLOBAL REGULATORY ENVIRONMENT

*Session Objectives:* Changes in the global regulatory environment of relevance to Africa will be presented.

#### 13:30 EU Regulatory Assessment Using Article 58

Dr. Marie Hélène Pinheiro, EMEA, EU, Scientific Administrator, Human Unit Regulatory Affairs Section

#### 13:50 WHO Prequalification Scheme

Dr. Lembit Rägo, WHO, Switzerland, Coordinator, Quality Assurance and Safety Medicines, Department of Medicines Policy and Standards

#### 14:10 Biosimilars

Dr. Eugene Corrette, sanofi-aventis R&D, France, Head, Cardiovascular Axis II, Regulatory Development Department

#### 14:30 Panel Discussion

15:00– Coffee Break  
15:30

### 15:30– SESSION 2 continued

17:00

#### 15:30 Update on ICH-GCG and Interface with Regional Harmonisation Initiatives

Dr. Yves Juillet, LEEM (Les Entreprises du Médicament)/IFPMA, France, Senior Advisor

#### 15:50 Experience and Successes of EU Accession

Dr. Marie Hélène Pinheiro, EMEA, EU, Scientific Administrator, Human Unit Regulatory Affairs Section

#### 16:10 Update on SADC Including the Perceived Benefits and Challenges of Harmonisation

Mr. Joseph Mthetwa, SADC, Senior Programme Manager for Healthcare and Pharmaceuticals

#### 16:30 Panel Discussion

#### 17:00 End of Day 1

#### 18:00 Networking Dinner

(The dinner will be an additional fee and we kindly ask you to register in advance.)

## Wednesday, February 6, 2008

07:30 Welcome Coffee

### 08:30– SESSION 3

#### 09:45 ASSURING PRODUCT QUALITY

*Session Objectives:* The goal of this session is to raise awareness of risk-based approaches to quality and to reinforce understanding of GMP and the role of PIC/S.

#### 08:30 ICH Quality

Industry Speaker Invited

#### 09:00 Quality Risk Management

Mr. Malcolm Brian Holmes, GlaxoSmithKline, UK, Director, Quality Assurance

09:45– Coffee Break  
10:15

### 10:15– SESSION 3 continued

11:45

#### 10:15 GMP and the Pharmaceutical Inspection Cooperation Scheme (PIC/S)

Mr. Robert Wayne Tribe, Bob Tribe Consultancy, Australia, GMP Consultant; Consultant to PIC/S; Former Chairman of PIC/S

#### 10:45 Journey into PIC/S

Dr. Joey Gouws, South African Department of Health, Director: Inspectorate & Law Enforcement

#### 11:15 Panel Discussion

11:45– Lunch Break  
13:00

### 13:00– SESSION 4

#### 14:30 CERTIFICATION – THE CPP AND ITS ROLE IN EARLIER PATIENT ACCESS TO MEDICINES

*Session Objectives:* This session aims to reinforce the value of the CPP in order to facilitate and accelerate the review process.

#### 13:00 WHO Certification Scheme

Dr. Lembit Rägo, WHO, Switzerland, Coordinator, Quality Assurance and Safety Medicines, Department of Medicines Policy and Standards

#### 13:30 The Place of the CPP in Guaranteeing Quality, Safety, and Efficacy

Mr. Adrian Waterson, AstraZeneca UK Limited, UK, Regional Regulatory Director

#### 14:00 Panel Discussion

14:30– Coffee Break  
15:00

### 15:00– SESSION 5

#### 16:30 ANTI-COUNTERFEITING MEASURES

*Session Objectives:* The purpose of this session is to provide an update and sharing of experiences.

#### 15:00 The Roles of the WHO IMPACT Groups

FDA Speaker Invited

#### 15:20 Industry Perspective of Counterfeits – Regulatory Implications

Mr. Kevin Moore, Eli Lilly, UK, Investigation Manager, Europe, Middle East, Africa

#### 15:40 Addressing the Counterfeit Issue

Prof. Dora Akunyili, National Agency for Food and Drug Administration and Control (NAFDAC), Director General; Vice Chair, WHO IMPACT Group

#### 16:10 Panel Discussion

### 16:30– CONFERENCE CLOSING

17:00 *Session Objectives:* Conclude the session and look at the next steps.

#### Wrap-up and Next Steps

Prof. Trevor M. Jones, CBE, Kings College London, UK

17:00 CONFERENCE ADJOURNED



## African Regulatory Conference

### Indaba Hotel Fourways, Johannesburg, South Africa

### 5-6 February 2008

*A forum for regulatory authorities and the pharmaceutical industry*

Please complete all sections of this form, and email to [dia@ripcord.za.com](mailto:dia@ripcord.za.com) or fax (international) +27 11 4822836 or local (South Africa) 0866 161575

### Personal Details

Title: \_\_\_\_\_ Surname: \_\_\_\_\_ First Name: \_\_\_\_\_  
 Preferred name for name Badge: \_\_\_\_\_  
 Position: \_\_\_\_\_  
 Organisation: \_\_\_\_\_  
 Postal Address: \_\_\_\_\_  
 Suburb/Town: \_\_\_\_\_ Postal Code: \_\_\_\_\_ State: \_\_\_\_\_  
 Country: \_\_\_\_\_  
 Phone: \_\_\_\_\_ Fax: \_\_\_\_\_  
 Mobile Phone: \_\_\_\_\_ E-Mail: \_\_\_\_\_  
 Dietary requirements:  Vegetarian  Halaal  Other \_\_\_\_\_  
 Physical disability needs (please specify): \_\_\_\_\_

### Registration Details

Registration Costs		
<b>Early Bird fees are applicable to registrations received on or before 15 January 2008</b>		Please check relevant box and insert fee
<input type="checkbox"/> Early Bird – Government	R 1,420.00	
<input type="checkbox"/> Early Bird - Industry International	R 13,490.00	
<input type="checkbox"/> Early Bird - Industry Regional - African Countries	R 3,550.00	
<input type="checkbox"/> Early Bird - Non-profit organization	R 2,665.00	
<b>These fees are applicable to registrations received after 16 January 2008</b>		
<input type="checkbox"/> Government	R 1,635.00	
<input type="checkbox"/> Industry – International	R 13,705.00	
<input type="checkbox"/> Industry Regional - African Countries	R 3,765.00	
<input type="checkbox"/> Non-profit organisation	R 2,880.00	
<input type="checkbox"/> Conference Dinner:	R 200.00	

**Total:** \_\_\_\_\_

### Accommodation

Standard single room R735 per night, bed and breakfast, excluding 1% Tourism Levy  
 Arrival date:..... Departure date:..... No of nights:.....  
 SHOULD YOU WISH DOUBLE/SHARING ACCOMMODATION, PLEASE CONTACT RIPCORD PROMOTIONS ON [dia@ripcord.za.com](mailto:dia@ripcord.za.com)

## Travel

### FLIGHT INFORMATION:

Arrival date:..... Arrival day:..... Arrival time:..... Flight number:.....  
Departure date:..... Departure day:..... Departure time:..... Flight number:.....

**PLEASE NOTE THAT THE ABOVE INFORMATION IS REQUIRED TO ARRANGE THE COMPLIMENTARY TRANSFER FROM THE AIRPORT TO THE HOTEL. SHOULD YOU NOT HAVE MADE TRAVEL ARRANGEMENTS YET, PLEASE ADVISE ONCE YOU HAVE DONE SO.**

## Additional information

I am interested in a Pre or post conference tour – please contact me for details

### PAYMENT INFORMATION:

Credit Card Type:  Visa  Mastercard  American Express  
Card #: \_\_\_\_\_ Exp. Date: \_\_\_\_\_

Name printed on card: \_\_\_\_\_ CVV (three digits on back of card): \_\_\_\_\_

Signature: \_\_\_\_\_

### CANCELLATION POLICY: On or before January 28, 2008

Administrative fee will be withheld from the refund amount: Industry = R1330 RAND, Regional/Local Industry = R500, Full-time Government = R170, Non-profit = R335

Cancellations must be in writing and be received by the cancellation date above. Cancellation notices should be emailed to [ellen.diegel@diahome.org](mailto:ellen.diegel@diahome.org) and [dia@ripcord.za.com](mailto:dia@ripcord.za.com). Registrants who do not cancel by that date and do not attend will be responsible for the full registration fee paid.

**Signature, accepting terms of cancellation policy (emailed forms will be deemed to be signed) \_\_\_\_\_**

### TRAVEL AND HOTEL:

OR Tambo International Airport is about 25 miles from the Indaba Hotel and Conference Centre. Attendees should make airline reservations as early as possible to ensure availability.

All hotel reservations will be at the Indaba Hotel and Conference Centre. Reservations will be made under the name used to register for the program, and will be made by Ripcord Promotions. Payment / Reservation must be guaranteed with a credit card. The card used to cover your registration fee will be used to guarantee your hotel reservation.

### MEETING INFORMATION:

USA: Contact Ellen Diegel at the DIA office by telephone +1-215-442-6158

Fax +1-215-293-5965 or email: [ellen.diegel@diahome.org](mailto:ellen.diegel@diahome.org).

All Registrations will be processed by Ripcord Promotions.

South Africa and other countries:

Ripcord Promotions – Phone: + 27 11 4822835

Email: [dia@ripcord.za.com](mailto:dia@ripcord.za.com)

ONCE YOUR REGISTRATION FORM HAS BEEN RECEIVED, AN EMAIL CONFIRMATION WILL BE FORWARDED TO YOU. SHOULD YOU NOT HAVE RECEIVED THIS CONFIRMATION WITHIN 48 HOURS OF REGISTRATION, PLEASE CONTACT RIPCORD PROMOTIONS ON [dia@ripcord.za.com](mailto:dia@ripcord.za.com)

Ripcord Promotions  
P.O. Box 91989, Auckland Park  
2006  
SOUTH AFRICA

Phone: +27 11 4822835  
Fax: +27 11 4822836 and 0866 161575 (local)  
E-Mail: [dia@ripcord.za.com](mailto:dia@ripcord.za.com)  
Web Page: [www.diahome.org](http://www.diahome.org)